Literature DB >> 25013489

High-throughput sequencing to identify miRNA biomarkers in colorectal cancer patients.

Yan Sun1, Lin Wang2, Sheng-Chao Guo1, Xiao-Bing Wu3, Xue-Hu Xu3.   

Abstract

The altered expression of microRNAs (miRNAs) is associated with a number of cancer types. The study of the association between the miRNA profile and cancer may be useful to identify potential biomarkers of certain types of cancer. In the present study, 19 miRNAs were identified by high-throughput sequencing in the serum of colorectal cancer (CRC) patients. A network analysis was performed based on a computational approach to identify associations between CRC and miRNAs. The present study may be useful to identify cancer-specific signatures and potentially useful biomarkers for the diagnosis of CRC. The network analysis of miRNA-target genes may aid in identifying altered miRNA regulatory networks that are involved in tumor pathogenesis.

Entities:  

Keywords:  biomarker; colorectal cancer; high-throughput sequencing; miRNA

Year:  2014        PMID: 25013489      PMCID: PMC4081398          DOI: 10.3892/ol.2014.2215

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Colorectal cancer (CRC) is an important contributor to cancer-related mortality and morbidity. Accumulated data has uncovered several critical genes and pathways important in the initiation and progression of CRC (1–3). Large-scale sequencing analyses have identified numerous recurrently mutated genes and chromosomal translocations (4–6). In addition, a number of microRNAs (miRNAs) have been previously reported to be associated with CRC (7,8). However, how miRNA changes contribute to colorectal tumorigenesis has not yet been defined. Further insight into these changes may identify potential biomarkers or therapeutic targets. miRNAs are small non-protein coding RNA molecules that regulate gene expression (9,10). miRNAs are important in crucial cellular processes, including development, differentiation, proliferation, apoptosis and metabolism (11,12). miRNAs have been proven to interact with potential oncogenes or tumor suppressors, and a number of miRNAs are differentially expressed in normal and neoplastic tissues and in tumors. The differential expression of miRNA has been previously evaluated as a predictive signature of cancer (13–17). The present study investigated the expression profile of miRNAs in the serum of CRC patients. In total, 19 miRNAs were identified by high-throughput sequencing. A network analysis was performed based on a computational approach to identify associations between CRC and miRNAs. The network analysis of miRNA-target genes may aid in identifying altered miRNA regulatory networks that are involved in tumor pathogenesis.

Materials and methods

Samples and RNA extraction

Primary tumor and neighboring non-tumorous tissues were obtained from five CRC patients. All samples were collected according to procedures approved by the Institutional Review Board of the Guangzhou Medical University (Guangzhou, China) and individuals can not be identified from data or images included in the present study. Tissue samples were flash frozen in liquid nitrogen and stored at −80°C until nucleic acid extraction. In total, 200 mg of fresh frozen tissues were used to isolate total RNA by phenol extraction (TRIzol reagent; Invitrogen, Life Technologies, Carlsbad, CA, USA). RNA concentration and purity were controlled by A NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) was used to measure the quantity, integrity and purity of the small RNA. Patients provided written informed consent and the study was approved by the ethics committee of the Third Hospital of the Guangzhou Medical University.

miRNA sequencing and sequence analysis

The miRNA expression profile was determined using the Ion Torrent PGM™ sequencer (Life Technologies). Briefly, the Ion Total RNA-Seq kit v2 (Life Technologies) was used to make small RNA libraries that preserve strand information. The templates were prepared using the Ion OneTouch™ system (Life Technologies), and small RNA analysis was performed using the Ion PGM™ sequencer. The miRNA sequences were analyzed by the Torrent Suite software (Life Technologies), and by miRWalk (http://mirwalk.uni-hd.de) and miRBase (http://www.mirbase.org). In addition, gene ontology (GO) and pathway analyses were performed using several tools that identify pathways and GO based on data sets from sequencing with the intent to identify miRNA-related genes and pathways. The tools include Ingenuity Systems Bioinformatics Software (Ingenuity Systems, Inc., Redwood City, CA, USA), FatiGO (http://fatigo.bioinfo.cnio.es) and Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/gds).

Results

Altered miRNA expression in CRC patients

The miRNA profiles of five pairs of solid tumor and adjacent tissues were compared. In total, 16 miRNAs exhibited higher expression in the solid tumor tissues, while three miRNAs exhibited higher expression profiles in the normal tissues; these are listed in Table I.
Table I

Identification of miRNAs with higher expression profiles in normal or solid tumor tissues.

Solid tumor tissuesNormal adjacent tissues
hsa-miR-135b-5phsa-miR-100-5p
hsa-miR-146a-5phsa-miR-138-5p
hsa-miR-148b-3phsa-miR-191-5p
hsa-miR-17-5p
hsa-miR-196a-5p
hsa-miR-200a-3p
hsa-miR-20a-5p
hsa-miR-21-5p
hsa-miR-223-3p
hsa-miR-27a-5p
hsa-miR-29b-3p
hsa-miR-30e-5p
hsa-miR-374b-5p
hsa-miR-4787-5p
hsa-miR-485-3p
hsa-miR-660-5p

miR/miRNA, microRNA; CRC, colorectal cancer.

GO and pathway analyses of miRNA target genes

The results of the GO analysis showed that a number of target genes are involved in cell proliferation and apoptosis. The pathway analysis showed that the transforming growth factor β and Toll-like signal pathways are also involved (Fig. 1 and 2).
Figure 1

GO analysis. A number of target genes were found to be involved in cell proliferation and apoptosis. BP, biological process; CC, celluar component; MF, molecular function; GO, gene ontology.

Figure 2

Pathway analysis. Transforming growth factor β and Toll-like signal pathways were found to be involved in cell proliferation and apoptosis.

Discussion

miRNAs are small non-coding RNAs that enhance the cleavage or translational repression of specific mRNAs with recognition site(s) in the 3′-untranslated region. Since the identification of the miRNAs, several large-scale studies have compared the profiles of miRNA expression patterns between non-tumor and tumor tissues (18,19). A number of lines of evidence have shown that miRNA expression is predictive of outcome in patients with solid tumors. In lung cancer, low levels of let-7a have been associated with a short survival time following surgery. In addition, previous miRNA microarray expression profiling of tumors and paired non-tumorous tissues has been performed in colon cancer patients to identify miRNA expression patterns associated with outcome, and high levels of miR-21 have been found to be associated with a short overall survival time, independent of other factors (19,20). In the current study, 19 miRNAs were identified by high-throughput sequencing. A network analysis was performed based on a computational approach to identify associations between CRC and miRNAs. The current study may be useful to identify cancer-specific signatures and potentially useful biomarkers for the diagnosis of CRC. The network analysis of miRNA-target genes may aid in identifying altered miRNA regulatory networks that are involved in tumor pathogenesis.
  20 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

2.  Sizing up miRNAs as cancer genes.

Authors:  Carlos Caldas; James D Brenton
Journal:  Nat Med       Date:  2005-07       Impact factor: 53.440

Review 3.  The diverse functions of microRNAs in animal development and disease.

Authors:  Wigard P Kloosterman; Ronald H A Plasterk
Journal:  Dev Cell       Date:  2006-10       Impact factor: 12.270

4.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Practice parameters for the management of rectal cancer (revised).

Authors:  Joe J Tjandra; John W Kilkenny; W Donald Buie; Neil Hyman; Clifford Simmang; Thomas Anthony; Charles Orsay; James Church; Daniel Otchy; Jeffrey Cohen; Ronald Place; Frederick Denstman; Jan Rakinic; Richard Moore; Mark Whiteford
Journal:  Dis Colon Rectum       Date:  2005-03       Impact factor: 4.585

6.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

7.  MicroRNA signatures in human ovarian cancer.

Authors:  Marilena V Iorio; Rosa Visone; Gianpiero Di Leva; Valentina Donati; Fabio Petrocca; Patrizia Casalini; Cristian Taccioli; Stefano Volinia; Chang-Gong Liu; Hansjuerg Alder; George A Calin; Sylvie Ménard; Carlo M Croce
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Clues to the pathogenesis of familial colorectal cancer.

Authors:  L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

9.  Diagnostic and prognostic microRNAs in stage II colon cancer.

Authors:  Troels Schepeler; Jørgen T Reinert; Marie S Ostenfeld; Lise L Christensen; Asli N Silahtaroglu; Lars Dyrskjøt; Carsten Wiuf; Frank J Sørensen; Mogens Kruhøffer; Søren Laurberg; Sakari Kauppinen; Torben F Ørntoft; Claus L Andersen
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

View more
  5 in total

1.  miR-219-5p suppresses the proliferation and invasion of colorectal cancer cells by targeting calcyphosin.

Authors:  Quhui Wang; Lirong Zhu; Yasu Jiang; Junfei Xu; Feiran Wang; Zhixian He
Journal:  Oncol Lett       Date:  2017-01-04       Impact factor: 2.967

2.  A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer.

Authors:  Eirik Høye; Bastian Fromm; Paul H M Böttger; Diana Domanska; Annette Torgunrud; Christin Lund-Andersen; Torveig Weum Abrahamsen; Åsmund Avdem Fretland; Vegar J Dagenborg; Susanne Lorenz; Bjørn Edwin; Eivind Hovig; Kjersti Flatmark
Journal:  NAR Cancer       Date:  2022-01-14

3.  Prediction and Validation of Hub Genes Associated with Colorectal Cancer by Integrating PPI Network and Gene Expression Data.

Authors:  Yongfu Xiong; Wenxian You; Rong Wang; Linglong Peng; Zhongxue Fu
Journal:  Biomed Res Int       Date:  2017-10-25       Impact factor: 3.411

4.  Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol.

Authors:  Guihua Sun; Ya-Wen Cheng; Lily Lai; Tsui-Chin Huang; Jinhui Wang; Xiwei Wu; Yafan Wang; Yasheng Huang; Jinghan Wang; Keqiang Zhang; Shuya Hu; Ji-Rui Yang; Yun Yen
Journal:  Oncotarget       Date:  2016-01-26

5.  MicroRNA-744 Inhibits Cellular Proliferation and Invasion of Colorectal Cancer by Directly Targeting Oncogene Notch1.

Authors:  Jian Shen; Minzhe Li
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.